CollaGenex Pharmaceuticals is Awarded $962,000 NIH Grant to Support Research of Potent Anti-Inflammatory Effects of Incyclinide
The grant will be paid over two years and will support CollaGenex's manufacturing and formulation development of incyclinide as well as preclinical studies by Gary Nieman, a research collaborator from the State University of New York, and Jay Zwischenberger, M.D., a research collaborator from the University of Texas, Galveston. Gary Nieman conducted earlier studies with incyclinide in models for acute inflammation, and he and Dr. Zwischenberger will conduct additional studies that should advance the Company's understanding of incyclinide's potent anti-inflammatory properties.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.